Effect of short-term levamisole therapy on delayed hypersensitivity. 1980

Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen

A randomized trial of short-term Levamisole treatment was undertaken in a cancer population unresponsive to dinitrochlorobenzene (DNCB) to determine whether this agent increased delayed hypersensitivity. Of 100 patients entered, 50 received Levamisole (150 mg daily x 3) during DNCB challenge. The other 50 patients were challenged but not given the drug. The conversion rate to DNCB+ was 20% (10/50) for those treated and 12% (6/50) for controls. The difference is not significant. When all 100 patients were considered there was a statistically significant inverse relationship between extent of disease and the incidence of conversion to a DNCB reactive state. Levamisole as given does not appear to have a major influence on delayed cutaneous hypersensitivity.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007111 Immunity, Cellular Manifestations of the immune response which are mediated by antigen-sensitized T-lymphocytes via lymphokines or direct cytotoxicity. This takes place in the absence of circulating antibody or where antibody plays a subordinate role. Cell-Mediated Immunity,Cellular Immune Response,Cell Mediated Immunity,Cell-Mediated Immunities,Cellular Immune Responses,Cellular Immunities,Cellular Immunity,Immune Response, Cellular,Immune Responses, Cellular,Immunities, Cell-Mediated,Immunities, Cellular,Immunity, Cell-Mediated,Response, Cellular Immune
D007428 Intradermal Tests Skin tests in which the sensitizer is injected. Passive Transfer Test,Prausnitz-Kustner Test,Intradermal Test,Passive Transfer Tests,Prausnitz Kustner Test,Test, Intradermal,Test, Passive Transfer,Test, Prausnitz-Kustner,Tests, Intradermal,Tests, Passive Transfer
D007978 Levamisole An antihelminthic drug that has been tried experimentally in rheumatic disorders where it apparently restores the immune response by increasing macrophage chemotaxis and T-lymphocyte function. Paradoxically, this immune enhancement appears to be beneficial in rheumatoid arthritis where dermatitis, leukopenia, and thrombocytopenia, and nausea and vomiting have been reported as side effects. (From Smith and Reynard, Textbook of Pharmacology, 1991, p435-6) L-Tetramisole,Levotetramisole,Decaris,Dekaris,Levamisole Hydrochloride,Solaskil,Hydrochloride, Levamisole
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004137 Dinitrochlorobenzene A skin irritant that may cause dermatitis of both primary and allergic types. Contact sensitization with DNCB has been used as a measure of cellular immunity. DNCB is also used as a reagent for the detection and determination of pyridine compounds. 1-Chloro-2,4-Dinitrobenzene,2,4-Dinitrochlorobenzene,Benzene, 1-Chloro-2,4-Dinitro-,Chlorodinitrobenzene,DNCB,1 Chloro 2,4 Dinitrobenzene,2,4 Dinitrochlorobenzene
D005260 Female Females

Related Publications

Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
January 1974, La Nouvelle presse medicale,
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
April 1981, Vrachebnoe delo,
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
July 1983, Antibiotiki,
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
June 1980, Clinical immunology and immunopathology,
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
December 1982, Transplantation proceedings,
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
November 1972, The Journal of infectious diseases,
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
August 1965, Cancer research,
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
February 1967, Journal of immunology (Baltimore, Md. : 1950),
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
January 1978, Acta dermato-venereologica,
Y Hirshaut, and C M Pinsky, and I Frydecka, and H J Wanebo, and S Passe, and V Miké, and H F Oettgen
May 1977, Lancet (London, England),
Copied contents to your clipboard!